Intravenous Lipid Emulsion as an Adjuvant Therapy of Acute Clozapine Poisoning: A randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR201911916675189

Enrollment

Registered

2019-11-26

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury, Occupational Diseases, Poisoning

Interventions

The standard supportive care plus SMOF Lipid infusion

The standard supportive carof acute clozapine poisoning.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients (male or female) with moderate to severe acute clozapine poisoning according to poisoning severity score .

Exclusion criteria

Exclusion criteria: 1. Asymptomatic and mild cases. 2. Pregnant and lactating women. 3. Patients with coingestion of other substances in addition to antipsychotics. 4. Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).

Design outcomes

Primary

Measure	Time frame
improvement of consciousness measured by the Glasgow Coma Scale	—

Secondary

Measure	Time frame
Intensive care unit (ICU) admission and/or mechanical ventilation,improvement in corrected QT interval, the duration of hospital stay, the total in hospital mortality.	—

Countries

Egypt

Contacts

Public Contactfatema elgazzar

Assistant Professor of Forensic Medicine and Clinical Toxicology Faculty of Medicine

fm.elgazzar@gmail.com00201004568919

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026